Orplatna Needs Overall Survival Data For Prostate Cancer Indication – ODAC
Executive Summary
Progression-free survival data for GPC Biotech's Orplatna are flawed and do not justify accelerated approval of the drug, FDA's Oncologic Drugs Advisory Committee concluded July 24
You may also be interested in...
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
FDA's final guidance on cancer endpoints has dropped a discussion on clinical trial designs that provide no treatment or use a placebo control
Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.